LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
116.16
+1.81 (+1.58%)
At close: 4:10PM EDT
Stock chart is not supported by your current browser
Previous Close114.35
Open115.93
Bid115.00 x 800
Ask116.46 x 1100
Day's Range114.47 - 117.23
52 Week Range104.17 - 132.13
Volume7,516,310
Avg. Volume3,786,059
Market Cap112.145B
Beta (3Y Monthly)0.24
PE Ratio (TTM)14.66
EPS (TTM)7.93
Earnings DateOct 23, 2019
Forward Dividend & Yield2.58 (2.26%)
Ex-Dividend Date2019-08-14
1y Target Est124.25
Trade prices are not sourced from all markets
  • What's next for Purdue Pharma after filing for bankruptcy
    Yahoo Finance Video

    What's next for Purdue Pharma after filing for bankruptcy

    Oxycontin maker Purdue Pharma filed for chapter 11 bankruptcy on Sunday, after reaching a tentative settlement with 24 states that accused the company of fueling the U.S. opioid crisis. Yahoo Finance's Alexis Keenan reports. William Soilman, Chairman and CEO of the Accreditation Council for Medical Affairs, further discusses with Yahoo Finance's Adam Shapiro and Julie Hyman.

  • 3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices
    GuruFocus.com

    3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices

    Stocks have outperformed the S&P; 500 over the past 12 months Continue reading...

  • CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
    PR Newswire

    CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial

    INDIANAPOLIS, Sept. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an update to the Trulicity® (dulaglutide) label and indication statement. The committee agreed the label should include results from the REWIND cardiovascular (CV) outcomes trial, which achieved a significant 12 percent risk reduction in major adverse cardiovascular events (MACE). The CHMP has recommended updating the Trulicity® indication to reflect both glycemic control and the impact on cardiovascular events as fundamental considerations in a treatment for people with type 2 diabetes.

  • Lilly Announces Webcast to Discuss ESMO 2019 Presentations
    PR Newswire

    Lilly Announces Webcast to Discuss ESMO 2019 Presentations

    INDIANAPOLIS , Sept. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society ...

  • How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
    Investor's Business Daily

    How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

    Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.

  • Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
    Zacks

    Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

    Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

  • AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
    Zacks

    AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure

    The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.

  • Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
    Zacks

    Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert

    The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.

  • Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival
    Zacks

    Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

    Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

  • Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
    Zacks

    Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

    Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.

  • GuruFocus.com

    Gilead Tops List of Most Innovative Drug Companies

    Index ranks ability of pharma companies to bring drugs from early testing to market and make them successful Continue reading...

  • Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks
    Zacks

    Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • Pfizer's Pneumococcal Vaccine Shows Potential in Infants
    Zacks

    Pfizer's Pneumococcal Vaccine Shows Potential in Infants

    Pfizer (PFE) announces positive preliminary data from mid-stage study evaluating its 20-valent pneumococcal conjugate vaccine in infants. Completes enrollment in late-stage studies on the vaccine in adults.

  • Top Analyst Reports for Caterpillar, General Motors & Citigroup
    Zacks

    Top Analyst Reports for Caterpillar, General Motors & Citigroup

    Top Analyst Reports for Caterpillar, General Motors & Citigroup

  • 10 Healthcare Stocks to Buy Despite the Headlines
    InvestorPlace

    10 Healthcare Stocks to Buy Despite the Headlines

    The past several weeks have been raucous ones for all stocks, but particularly wild ones for healthcare stocks. Not only is the future of the nation's healthcare market in flux, drug companies are facing an inordinate degree of litigation, and biopharma names have dished out plenty of R&D updates … some good, some bad.By and large, the bearish market-wide tide and the weakness healthcare stocks have suffered has become something of an opportunity. A handful of these names have become bargains and are ripe for recoveries. * 10 Stocks to Sell in Market-Cursed September To that end, here's a rundown of ten healthcare stocks to buy, even if they're surrounded by bad news and grim headlines. Some are familiar, and others are not. All of them, however, arguably boast more potential than risk at this time, even if not all of them have yet to reach their worst-case-scenario price.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Source: Sundry Photography / Shutterstock.com Johnson & Johnson (NYSE:JNJ) has arguably faced the worst and most alarming headlines of late, facing not one but two major legal battles.The first one of course is its liability linked to asbestos contained in its talcum powder sold under the brand name Johnson & Johnson. The other? Some states' attorneys general are suggesting J&J was culpable for what's turned into a nationwide opioid addiction epidemic. A closer inspection of both matters reveals the ultimate liability for both may not be as dire as is currently believed.Though the state of Oklahoma recently won a case that will fine Johnson & Johnson $572 million for allowing opioid abuse to become a "public nuisance," that figure was smaller than shareholders had feared, and may point to similarly small figures in other state-level cases.As for its talcum powder woes, the company is prevailing in some state courts, and losing in others. With the exception of one case in California, the awards granted in cases it has lost have been relatively modest. AbbVie (ABBV)Source: Piotr Swat/Shutterstock AbbVie (NYSE:ABBV) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August.The underpinnings for that weakness aren't difficult to deduce. Aside from an increasingly tough battle to defend its patents on breadwinner drug Humira, the decision to acquire Allergan (NYSE:AGN) hasn't been a particularly popular one with shareholders.ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company's work in turning Rova-T into a successful lung cancer treatment, for instance, was thrown away when AbbVie ended phase 3 trials after it failed to create meaningful results. * 7 "Boring" Stocks With Exciting Prospects The punishment, so to speak, hasn't fit the crime though. AbbVie now quietly rates as one of the top healthcare stocks to buy at its now greatly-lowered price thanks to a dividend yield of 6.44% that's reasonably well protected, and a forward-looking P/E of only 7.. CVS Health (CVS)Source: Shutterstock Admittedly, it remains unclear which sliver of the healthcare market will be the one to bear the brunt of any cost-cutting reform. Hospitals and insurers are just as targeted as pharmacy names like CVS Health (NYSE:CVS), which is a key part of the reason CVS stock has been nearly cut in half since the middle of 2015.That doubt is rooted in a paradigm shift that isn't likely to happen, however, or at least not as abruptly as some are fearing.Case in point: Just days after announcing plans to eliminate the rebate enjoyed by pharmacies and pharmacy benefits managers, President Donald Trump backpedaled. Although it's not clear where the pressure for the reversal came from, clearly someone is in the industry's corner.In the meantime, CVS is preparing for all contingencies. It now owns health insurer Aetna and is tiptoeing into the medical device arena. In July the company announced it was beginning trials of an at-home kidney dialysis solution. Bausch Health Companies (BHC)Source: n4i Via FlickrYou may recognize the name as one that has specialized in eye care for a long time now. And Bausch -- Bausch + Lomb, to be precise -- certainly still makes contact lenses and eye-surgery products. This is not the Bausch Health Companies (NYSE:BHC) in question, however. While Bausch Health owns and operates Bausch + Lomb, the Bausch that has earned a spot on a list of healthcare stocks to buy is actually the company formerly known as Valeant Pharmaceuticals.That name will also ring a bell for most investors … although not a good one. That's the company that went on an aggressive acquisition spree, planning on buying specialty drugs to then mark their price up to unnecessarily expensive levels.In addition to public outcry, congress got involved, ultimately forcing then-CEO Michael Pearson out, and forcing new CEO Joseph Papa to rebuild everything the company is, and does. * 7 Best Stocks That Crushed It This Earnings Season Surprise! He's doing it. Though it's still erratic and somewhat unpredictable, sales are expected to grow 1.6% this year, and 3% next. It's not much, but it's enough to drive real earnings growth. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Intercept Pharmaceuticals (NASDAQ:ICPT) isn't an easy name to own. Although the biopharma outfit is driving major sales growth with its chronic liver disease drug Ocaliva, the company's a one-trick pony that's still losing money. Last quarter's top line of $66.3 million -- mostly Ocaliva -- was up 53% year-over-year, but still let Intercept book an operating loss of $63.6 million and a total net loss of $71.4 million.In this case though, the company's fiscal trajectory against the backdrop of an obesity epidemic translates into a bright future. Intercept Pharmaceuticals is also working on a nonalcoholic steatohepatitis (NASH) drug that takes aim at what is expected to be the leading cause of liver failure by 2020. That under-served market could be worth $50 billion, if not more, leaving this company amazingly well-positioned for growth. Pfizer (PFE)Source: Manuel Esteban/Shutterstock Stripping out last month's 20% stumble, Pfizer (NYSE:PFE) has been a pretty good bet in recent years. Thing is, the aspects that have made PFE stock one of the best healthcare stocks to buy for a long while now are still in place. That is, a diverse portfolio that doesn't lean too much on any one drug. No one product accounts for more than 10% of the company's total revenue.The selloff, for the record, was spurred by the decision to sell its 'off patent' drug business operating as Upjohn to rival Mylan (NASDAQ:MYL). The downside of that exit appears to be fully priced in now though, and then some. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off In the meantime, a $500 million investment in a North Carolina manufacturing facility pushes the company deeper into gene therapy waters, which may offer more upside than existing business lines. PRA Health Sciences (PRAH)Source: Shutterstock When investors thinks of healthcare stocks, PRA Health Sciences (NASDAQ:PRAH) isn't a name that generally comes to mind. Indeed, most investors may have never even heard of it.The one who have heard of it, meanwhile, might be wishing they hadn't. Even with this year's choppy rebound effort, shares of the contract research organization are still down 19%.A bet against PRA Health Sciences hasn't been a particularly wise bet in the grand scheme of things. Contracted research is a key part of the future of healthcare, as outsourcing R&D becomes the more cost-effective solution.PRA Health has the numbers to prove it, too. This year's expected 6.4% revenue growth isn't jaw-dropping, but it's reliable, as will be next year's projected 8.4% top-line growth. Better still, that progress is driving even greater profit growth. Per-share profits are expected to reach $5.03 this year, up from last year's $4.28, and grow 13% to $5.68 per share next year. Alexion Pharmaceuticals (ALXN)Source: Shutterstock Last week, Alexion Pharmaceuticals (NASDAQ:ALXN) shares started what would end up becoming a 14% plunge. The selloff may not be done yet either. The prod? Amgen (NASDAQ:AMGN) is challenging Alexion's patent on Soliris, which is used to treat a trio of rare diseases. It makes up the bulk of Alexion's sales.It's an alarming development, although not one that's necessarily devastating. Right or wrong, running patent-based interference meant to disrupt other companies is the new norm within the pharmaceuticals arena, and there's not necessarily any assurance that Amgen will prevail. The chatter that Amgen could make an acquisition bid for Alexion still has its merits as well. * 10 Buy-and-Hold Stocks to Own Forever In the meantime, the forward-looking P/E of 9.9 suggests ALXN is priced cheaply enough to survive any profit-sharing agreement that Amgen may end up pursuing instead of an outright legal victory. Cigna (CI)While pharmacies and pharmaceuticals are certainly vulnerable to any sweeping overhauls in the way the United States healthcare industry works, it's not like the insurers are particularly well-shielded. Cigna (NYSE:CI), for instance, is down more than 30% since its early 2018 high on concerns about insurers' futures, after they all had a pretty good run between 2013 and 2017.Not everyone is concerned about one of a myriad of 'maybes' that could impact Cigna though.Alliance Bernstein analyst Lance Wilkes is one of those optimists. He recently upgraded CI stock while it was down, re-rating it at an "Outperform," explaining "We are increasing our price target and rating on [Cigna] based upon earnings growth driven from deal synergies and its low valuation, which we believe offset our [long term] concerns on policy risks and strategic position."CI stock is trading at only 14 times its trailing earnings, and only 8.2 times next year's expected profits. Eli Lilly (LLY)Source: Shutterstock Finally, add drugmaker Eli Lilly (NYSE:LLY) to your list of healthcare stocks to buy despite a recent wave of bad news.For Lilly, that's mostly been spurred by pipeline and portfolio questions. In March it announced it would launch a cheaper alternative to its own top-selling Humalog insulin, and early this year it decided to acquire Loxo Oncology at an unpopularly frothy premium.There's a reason that slide suffered during the first half of the year has started to reverse course beginning in early August. Not only did Lilly win the outcome it wanted in a recent arbitration claim regarding a collaboration it entered with Adocia to develop rapid-acting insulin, a phase 3 trial of its oral JAK inhibitor Baricitinib as a therapy for atopic dermatitis showed tremendous promise with last month's update.They're little victories that can really add up in investors' heads.As of this writing, James Brumley held no position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post 10 Healthcare Stocks to Buy Despite the Headlines appeared first on InvestorPlace.

  • Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
    Zacks

    Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

  • Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study
    Zacks

    Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

    Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.

  • Novartis Announces Positive Long-Term Data on Migraine Drug
    Zacks

    Novartis Announces Positive Long-Term Data on Migraine Drug

    Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.

  • [video]Eli Lilly's Must-Hold Level on Drug-Data Pullback
    TheStreet.com

    [video]Eli Lilly's Must-Hold Level on Drug-Data Pullback

    Eli Lilly stock is falling on the day after releasing clinical trial data. Here's the must-hold spot for LLY stock now.

  • Barrons.com

    Eli Lilly Stock Shrugs Off Upbeat Drug Data

    One analyst said that new data on an Eli Lilly cancer drug “could not have been better,” but the pharma giant’s stock was mildly lower in Monday morning trading.

  • TheStreet.com

    Eli Lilly's Lung Cancer Treatment Candidate Shows Strong Results in Trial

    Eli Lilly are falling Monday despite the fact that the drug company announced that its experimental cancer drug shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene. RET abnormalities occur in about 2% of non-small cell lung cancers, between 10% and 20% of papillary thyroid cancers and about 60% of medullary thyroid cancers. Eli Lilly acquired the drug, LOXO-292, as part of its $8 billion acquisition of Loxo Oncology in January.

  • Reuters

    Lilly's targeted RET drug shrinks tumors in lung cancer trial

    Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene. The results, presented on Monday at the World Lung Conference on Lung Cancer in Barcelona, will support Lilly's application for U.S. Food and Drug Administration approval later this year. "At the beginning of this year, we put a bet on Loxo," Dr. Daniel Skovronsky, Lilly's chief scientific officer, said in a telephone interview.

  • Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
    PR Newswire

    Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

    - LIBRETTO-001 is the largest trial ever reported in RET-altered cancer patients - 68 percent objective response rate (ORR) in the registration dataset (n=105) of RET fusion-positive NSCLC patients who ...

  • Benzinga

    The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

    The holiday-shortened week saw a few huge moves by individual stocks. Abeona Therapeutics Inc (NASDAQ: ABEO ) was among the biggest gainers after the biopharma announced plans to explore strategic alternatives. ...

  • Reuters

    UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.

    Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.